NCT07501325

Brief Summary

This study will evaluate whether blood tests that measure IgE antibodies to two shrimp proteins, tropomyosin and hemocyanin, can help diagnose shrimp allergy in children. Children with suspected IgE-mediated shrimp allergy will undergo oral food challenge, skin prick testing, and blood sampling. Oral food challenge results will be used as the reference standard to determine whether these tests can accurately identify true shrimp allergy and help improve diagnosis in clinical practice.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
129

participants targeted

Target at P50-P75 for not_applicable

Timeline
20mo left

Started Apr 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress17%
Apr 2026Apr 2028

First Submitted

Initial submission to the registry

March 24, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 30, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2028

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2028

Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

1.9 years

First QC Date

March 24, 2026

Last Update Submit

March 24, 2026

Conditions

Keywords

Oral Food ChallengeSkin Prick TestTropomyosinHemocyaninSpecific IgERecombinant Allergenshrimp allergyShellfish AllergyChildren

Outcome Measures

Primary Outcomes (1)

  • Oral Food Challenge-Confirmed IgE-Mediated Shrimp Allergy

    Participants will be classified as having true IgE-mediated shrimp allergy if the oral food challenge is positive according to the study protocol. A negative oral food challenge indicates shrimp tolerance. Oral food challenge results will be used as the reference standard for subsequent diagnostic performance analyses.

    At the time of the oral food challenge during the baseline diagnostic evaluation

Secondary Outcomes (3)

  • Diagnostic Accuracy of Recombinant Tropomyosin-Specific IgE for Oral Food Challenge-Confirmed Shrimp Allergy

    During the baseline diagnostic evaluation

  • Diagnostic Accuracy of Recombinant Hemocyanin-Specific IgE for Oral Food Challenge-Confirmed Shrimp Allergy

    During the baseline diagnostic evaluation

  • Diagnostic Accuracy of a Combined Model Incorporating Recombinant Tropomyosin-Specific IgE, Recombinant Hemocyanin-Specific IgE, Clinical History, and Skin Prick Test

    During the baseline diagnostic evaluation

Study Arms (1)

Children With Suspected IgE-Mediated Shrimp Allergy

EXPERIMENTAL

Children with suspected IgE-mediated shrimp allergy who undergo the study procedures, including oral food challenge, skin prick testing, and blood sampling for measurement of recombinant tropomyosin- and hemocyanin-specific IgE. Oral food challenge will be standardized using black tiger shrimp (Penaeus monodon), with additional challenge using other shrimp species when clinically indicated.

Diagnostic Test: Oral Food Challenge (OFC)Diagnostic Test: Skin Prick TestDiagnostic Test: Recombinant Tropomyosin- and Hemocyanin-Specific IgE Measurement

Interventions

Oral food challenge with shrimp performed according to the study protocol to confirm or exclude IgE-mediated shrimp allergy in children with suspected shrimp allergy. To standardize the challenge material, black tiger shrimp (Penaeus monodon) will be used in all participants. Additional oral food challenges using other shrimp species may be performed when the clinical history suggests reactions to a different shrimp species. The oral food challenge result serves as the reference standard for diagnostic evaluation in this study.

Children With Suspected IgE-Mediated Shrimp Allergy
Skin Prick TestDIAGNOSTIC_TEST

Skin prick testing performed as part of the diagnostic evaluation in children with suspected IgE-mediated shrimp allergy.

Children With Suspected IgE-Mediated Shrimp Allergy

Blood testing to measure specific IgE to recombinant tropomyosin and hemocyanin as part of the diagnostic evaluation of suspected shrimp allergy.

Children With Suspected IgE-Mediated Shrimp Allergy

Eligibility Criteria

Age1 Year - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 1 to 16 years.
  • Evaluated at the Allergy Unit of Children's Hospital 1.
  • Clinical history suggestive of IgE-mediated shrimp allergy based on EAACI 2023 criteria, including at least 1 typical allergic symptom (urticaria, angioedema, vomiting, abdominal pain, diarrhea, cough, wheezing, dyspnea, or hypotension), symptom onset within 2 hours after shrimp ingestion, and recurrence on at least 2 separate exposures.
  • Parent or legal guardian able to provide written informed consent; child assent obtained when appropriate.

You may not qualify if:

  • Acute illness at the time of enrollment or challenge, including acute respiratory infection, acute gastrointestinal infection, or acute asthma exacerbation.
  • Severe chronic disease, including malignancy, severe liver or kidney disease, primary immunodeficiency, or significant heart disease affecting hemodynamic status.
  • Mental or behavioral disorder that prevents completion of study procedures.
  • Use of immunosuppressive medication (oral corticosteroids, cytotoxic drugs, or biologic agents) within 4 weeks before enrollment, or intravenous immunoglobulin within the previous 3 months.
  • Acute illness at the time of enrollment or challenge, including acute respiratory infection, acute gastrointestinal infection, or acute asthma exacerbation; participants may be rescheduled after recovery.
  • Severe chronic disease, including malignancy, severe liver or kidney disease, primary immunodeficiency, or significant heart disease affecting hemodynamic status.
  • Mental or behavioral disorder that prevents completion of study procedures.
  • Use of immunosuppressive medication (oral corticosteroids, cytotoxic drugs, or biologic agents) within 4 weeks before enrollment, or intravenous immunoglobulin within the previous 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Hospital 1, Ho Chi Minh City, Vietnam

Ho Chi Minh City, Vietnam

Location

MeSH Terms

Conditions

Food HypersensitivityShellfish Hypersensitivity

Interventions

Patch Tests

Condition Hierarchy (Ancestors)

Hypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

Skin TestsImmunologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesImmunologic Techniques

Study Officials

  • Tu HK Trinh, MD, PhD

    University of Medicine and Pharmacy at Ho Chi Minh City

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ngoc Thi Nguyen, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
No masking is used for study assignment. However, laboratory personnel performing recombinant tropomyosin- and hemocyanin-specific IgE measurements are independent of the clinical team and are blinded to participants' oral food challenge results at the time of laboratory assessment.
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: All enrolled children with suspected IgE-mediated shrimp allergy will undergo the same study procedures, including oral food challenge, skin prick testing, blood sampling, and measurement of recombinant tropomyosin- and hemocyanin-specific IgE.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD Student

Study Record Dates

First Submitted

March 24, 2026

First Posted

March 30, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

April 1, 2028

Last Updated

March 30, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations